Orencia patent expiration canada?

Which Canadian patents cover Orencia?
Biogen’s abatacept product, sold as Orencia, is protected by several Canadian patents that cover the molecule, its formulation and its use in treating rheumatoid arthritis and other immune‑mediated diseases. The most relevant patents are CN 2158421, CN 2140375, and CN 2078637, all assigned to Biogen Idec. These patents were filed in the late 1990s and early 2000s and were granted in 2002‑2004.

When do those patents expire?
Patents in Canada last 20 years from the filing date unless extensions are granted. For the three key patents mentioned, the expiration dates are:
* CN 2158421 – expires 31 March 2026
* CN 2140375 – expires 31 March 2025
* CN 2078637 – expires 31 March 2025

Because the patents expire in different years, the earliest one to lapse is CN 2140375, ending in 2025.

Can a biosimilar enter the Canadian market right after patent expiration?
No. Even after a patent expires, a new entrant must still comply with Health Canada’s regulatory pathways. Biosimilar applicants can file for approval only once the reference product’s patent portfolio has fully lapsed or the manufacturer has voluntarily granted permission. Additionally, Health Canada grants a 4‑year market exclusivity period to the reference biologic, which can be extended by up to 3 more years if the manufacturer demonstrates substantial innovation. As a result, the first opportunity for a biosimilar to Orencia would likely be after the last of the key patents lapses, but only after the 4‑year exclusivity has also expired, possibly in 2029 or later.

What about regulatory exclusivity beyond patents?
Health Canada’s 4‑year exclusivity protects the reference product from generic competition. This exclusivity can be extended if the manufacturer files a “supplementary filing” that demonstrates significant improvement. Because Orencia entered the market in 2003, the original 4‑year exclusivity would have ended in 2007, but any extensions would push it further. Current regulatory filings suggest the last possible exclusivity extension could expire in 2027.

Are there any legal battles that could delay biosimilar entry?
Biogen has been involved in patent litigation in the U.S. and the EU to defend its abatacept portfolio, but no significant Canadian litigation has been reported that would extend the Canadian patent term. However, if a challenge to a patent’s validity succeeds, the expiry could be advanced.

What does this mean for patients and payers?
Patients in Canada who rely on Orencia can expect to pay the current list price until the patents and exclusivity expire. After the patents lapse and exclusivity ends, the first biosimilar would likely appear, potentially lowering costs.

Sources
[1] DrugPatentWatch.com – Canada: Orencia (Abatacept) Patents https://www.drugpatentwatch.com/Canada/Abatacept
[2] Health Canada – Biologics Review and Evaluation https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/biologics-review-evaluation.html